Please login to the form below

Not currently logged in


This page shows the latest Seretide news and features for those working in and with pharma, biotech and healthcare.

Is GSK planning to exit the respiratory business?

Is GSK planning to exit the respiratory business?

Much of its recent success was built on the back of combination therapies that were first introduced in the late 1980s, and culminated in its blockbuster Advair/Seretide (salmeterol/fluticasone propionate)

Latest news

More from news
Approximately 9 fully matching, plus 90 partially matching documents found.

Latest Intelligence

  • Back to the future Back to the future

    Only Seretide/Advair ($8.4bn), Abilify ($8bn) and Crestor ($6.9bn) prevented a biologic clean sweep of the bestsellers.

  • What can pharma learn from Olympic sports coverage? What can pharma learn from Olympic sports coverage?

    Over the years, the corporation has built a wealth of knowledge in the field, and built and maintained a leading portfolio of respiratory products from Ventolin in 1969 through to Seretide,

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...